The Link of Actos and Bladder Cancer. New plaintiffs claiming a link between Actos and bladder cancer are still coming forward years after lawsuits concerning the risk of Actos side effects were first filed.
The plaintiffs allege they were not sufficiently warned about the potential risk of dangerous side effects and were seriously harmed, reports LawyersandSettlements.com.
According to the Louisiana Record, in June 2016, in a lawsuit recently filed, the plaintiff alleges he used Actos from 2004 through 2010 and was diagnosed with bladder cancer which he claims is directly tied to his use of Actos.
The plaintiff’s lawsuit claims permanent injuries, pain, suffering, and mental anguish. Similar to other lawsuits, the plaintiff alleges that Takeda Pharmaceuticals was negligent in warning patients or healthcare providers about the bladder cancer risk, LawyersandSettlements.com reports.
Actos lawsuits have been consolidated for pretrial proceedings
Actos lawsuits have been consolidated for pretrial proceedings in a multidistrict litigation (MDL). As of June 15, 2016, there were more than 4,500 lawsuits have been consolidated in the MDL.
In a March 30, 2016 study published in the British Medical Journal (BMJ), it was suggested Actos (pioglitazone) is linked to a 63 percent increased risk of bladder cancer, and the risk is specific to Actos.
The risk did not appear in similar drugs in the same class, such as rosiglitazone. Researchers also discovered that the duration and dose had an effect on the development of bladder cancer risk.
Takeda has settled some lawsuits filed by plaintiffs who claimed they developed bladder cancer after using Actos diabetes medication. Takeda has also lost some lawsuits that went to court, where juries awarded millions of dollars in damages, according to LawyersandSettlements.com.